In a nutshell This study investigated the effectiveness and side effects on the heart of anthracycline-based therapies (ABTs) for breast cancer. They found that non-doxorubicin (non-DXR) ABTs had a better benefit/risk ratio (BRR) than DXR alone. Some background Anthracycline-based therapies (ABTs) are commonly used to treat breast...
Read MoreBreast cancer Posts on Medivizor
Trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer
In a nutshell This study wanted to find out which treatment was better before surgery for patients with HER2-positive breast cancer, trastuzumab emtansine (Kadcycla) plus pertuzumab (Perjeta), or a standard treatment. The study found that patients treated with trastuzumab emtansine plus pertuzumab (TEP) were more likely to have cancer...
Read MoreEarly breast cancer – a review of treatment guidelines.
In a nutshell This study reviewed early breast cancer (EBC) treatment guidelines. Some background Breast cancer (BC) is a common and treatable form of cancer. Understanding treatment options is important to improve patient care. Treatment options include surgery and radiotherapy (RT). Adjuvant systemic treatment (AST) is a non-surgical option. AST...
Read MoreNanodrugs
Nanodrugs have been around for some time. In fact, over 250 drugs using nanotechnology that have been approved by the FDA and are in clinical use. The name nanodrug or nanopharmaceuticals refers to the size of the particle that is created to house the medication. A nano is very tiny: nanoparticles are between 1 and 100 nanometers in at least one of its...
Read MoreSearching for patients with unresponsive cancer to test a new treatment
In a nutshell This phase 1/2 trial will investigate the safety of 9-ING-41, for treatment-resistant cancers. The main outcome will be the number of treatment-related adverse events (TRAEs). This trial is recruiting in the United States. The details Some cancers may not respond to conventional treatment. Treatment-resistant cancers are called...
Read MoreLooking patients with metastatic triple negative breast cancer to trial a radiation treatment
In a nutshell This phase 2 trial will investigate the effectiveness of stereotactic body radiotherapy (SBRT) in patients with metastatic cancer. The main outcome will be progression-free survival (PFS; survival without the cancer getting worse). This trial is recruiting in multiple locations in New York and New Jersey, US. The details...
Read MoreSearching for patients with advanced breast cancer to trial a new treatment.
In a nutshell This trial aims to find out how safe talazoparib (Talzenna) followed by a combination of talazoparib and avelumab (Bavencio) is in patients with advanced breast cancer. The main outcome that will be measured is if patients have side effects. This study is being conducted in Washington, the United States. The...
Read MoreLooking for patients with breast cancer on hormonal therapy to trial a new drug for vasomotor symptoms
In a nutshell This phase 2 trial will investigate the effectiveness of Q-122, an experimental drug to treat hot flashes in breast cancer (BC). The main outcome will be the hot flash severity score (HFSS). This trial is recruiting in the United States and Australia. The details Breast cancer (BC) is one of the most common cancers in women....
Read MoreLooking for patients with advanced triple negative breast cancer to test a new drug
In a nutshell This phase 1 study will investigate the dose range and effectiveness of an experimental drug, XmAb23104, in the treatment of advanced breast cancer and other solid tumors. The main outcome will be the safety and tolerability of XmAb23104. This trial is recruiting in Georgia, Texas, and Virginia, the United States. The details...
Read MoreSearching for patients with advanced triple negative breast cancer to trial a new treatment into the tumor
In a nutshell This phase 2 study will investigate Tavokinogene Telseplasmid Electroporation (TTE) in combination with pembrolizumab (Keytruda) in advanced or not suitable for surgery triple-negative breast cancer (TNBC). The main outcome will be the objective response rate (ORR). This trial is recruiting in the United States and...
Read MoreSearching for patients with triple negative breast cancer to test durvalumab and olaparib
In a nutshell This phase 2 study will investigate the safety and effectiveness of olaparib (Lynparza) alone or in combination with durvalumab (Infinzi) in advanced triple negative breast cancer (TNBC). The main outcome will be progression-free survival (PFS). This study is recruiting in Durham, North Carolina, US. The details...
Read MoreLisinopril versus carvedilol to prevent trastuzumab-related heart problems in patients with breast cancer.
In a nutshell This study wanted to find out if lisinopril (Zestril) or carvedilol (Coreg) can help prevent heart problems in patients with HER2 positive breast cancer who are treated with trastuzumab (Herceptin). The study found that both of these medications helped reduce the chance of heart problems in these patients if they were also being...
Read More
